Director of Blood and Bone Marrow Transplant
Dr. Lloyd Damon is director of the adult Blood and Marrow Transplant and Hematologic Malignancies Program and chief of the UCSF Hematology Clinic. He is a hematologist, cancer specialist or oncologist, and researcher who specializes in cancers of the blood such as lymphomas and leukemias. In his research, he studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was one of the early investigators in the first monoclonal antibody, called rituximab, approved to treat human cancer, specifically lymphoma. In 1998, he developed a high-dose regimen involving autologous stem cell transplants for mantle cell lymphoma. He also discovered the risk factors for an uncommon brain side effect of an important leukemia drug, cytarabine, and developed a dose modification algorithm that reduced this side effect to extremely low levels.
Damon earned a medical degree at the University of Michigan. He completed an internal medicine residency and hematology-oncology fellowship at UCSF, where he joined the faculty in 1988. He is a professor of clinical medicine and deputy chief of the Division of Hematology and Medical Oncology at UCSF.
Hematology and Blood and Marrow Transplant
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Hours: Monday to Friday
8 a.m. – 5 p.m
University of Michigan 1982
UCSF, Internal Medicine 1985
UCSF, Hematology/Oncology 1988
Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.